You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Dr Reddys Lab launches cancer drug in US

Capital Market 

The drug major announced the launch of capecitabine tablets, a therapeutic equivalent generic version of Xeloda tablets, approved by the U.S. Food and Drug Administration (USFDA).

Capecitabine is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Dr. Reddy's capecitabine tablets, USP are available in 150mg and 500mg strengths in bottle count sizes of60 and 120, respectively.

The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.

Dr. Reddy's Laboratories is an integrated pharmaceutical company. The scrip fell 1.79% to Rs 4612, extending decline for fourth day. The stock has declined by 4.4% in four sessions.

In the past one month, the stock has corrected by 11.46% while the benchmark Sensex has added 5.98% during the same period.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, February 17 2021. 12:09 IST